Drugnews

What are the Pfizer SSGJ-707 deal terms?

On May 19, 2025, Pfizer announced a license for 3SBio’s SSGJ-707 with a $1.25 billion upfront payment and up to $4.8 billion in development, regulatory and commercial milestones. Those components sum to a potential $6.05 billion before royalties; the separately announced $100 million equity investment is not part of that licensing total.

Updated

Announced consideration in US dollars; royalties excluded
MeasureReported resultBasis
Upfront payment$1.25 billionLicense consideration
Potential milestonesUp to $4.8 billionConditional development, regulatory and commercial payments
Potential license totalUp to $6.05 billionCalculated: upfront plus maximum milestones
Separate equity investment$100 millionExcluded from the license total

Ivonescimab after the FDA letter

On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.

November 17, 2026 analysis

Sources

Read the full analysis

FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026